NCT06724237View on ClinicalTrials.gov

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

April 30, 2028

Study Completion Date

December 1, 2033

Conditions
Anaplastic Large Cell Lymphoma, ALK-NegativeFollicular Helper T-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypePeripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo ASCT

OTHER

Best Practice

Receive standard of care observation

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

DRUG

High Dose Chemotherapy

Receive high dose chemotherapy

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

DRUG

Stem Cell Mobilization Therapy

Receive stem cell mobilization therapy

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK

NCT06724237 - Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | Biotech Hunter | Biotech Hunter